REAL-WORLD DATA (RWD) / REAL-WORD EVIDENCE (RWE) INSIGHTS
-
![Measuring-oxygen-saturation level-GettyImages-1392177599]( "Embracing Hybrid Trial Design — How, When, & Why To Use It")
Embracing Hybrid Trial Design — How, When, & Why To Use ItGlobal Clinical Sciences & Operations Innovation Lead Lewis Millen talks about UCB’s approach to hybrid trial design, how and when it chooses to implement remote and virtual elements, and why a hybrid trial is beneficial to both the sponsor and the patient.
-
![Nervous-anxiety-GettyImages-1409928195]( "Using RWD For Rapid Signal Assessment: Current Gaps And Opportunities")
Using RWD For Rapid Signal Assessment: Current Gaps And OpportunitiesOne of the chief benefits of applying RWD for rapid signal assessment is that it can provide a more accurate view of outcomes that should be expected within a given clinical scenario. However, before RWD’s maximum potential for rapid signal assessment can be reached, the industry must overcome some sizable challenges. Amgen's Vaishali Patadia explains.
RWD/RWE VIDEOS
Looking to minimize time on outreach or accelerate patient recruitment? Uncover how this partnership was able to deliver positive overall results for sponsors, ultimately benefiting patients.
Watch as clinical trial experts present how life science professionals can incorporate real-world data (RWD) and patient tokenization into their clinical development value streams.
Castor joins experts from United Biosource (UBC) and Datavant to discuss all things real-world evidence, patient-centric technologies, and the role of tokenization in clinical research.
Speed up trial recruitment with clinical alerts driven by artificial intelligence that identify patients on the pathway toward a diagnosis or therapy switch.
RWD/RWE RESOURCES
-
![GettyImages-1291478674 data manage ps]( "Choosing An EDC With A Robust API For DTx Clinical Trials")
Choosing An EDC With A Robust API For DTx Clinical TrialsThis white paper explores the importance of choosing an EDC with an API before starting a clinical trial.
-
![Scientist With iPad GettyImages-1195694221]( "Comprehensive Data Management For Non-Interventional Research")
Comprehensive Data Management For Non-Interventional ResearchLearn how your teams can embrace end-to-end clinical trial data platforms for non-interventional studies to improve user experience, boost patient engagement, ensure data quality, and achieve study success.
-
![Thinking Pragmatically About The Future Of Real World Evidence]( "Single-Arm Trials Use Real-World Evidence For Rare Disease Drug Development")
Single-Arm Trials Use Real-World Evidence For Rare Disease Drug DevelopmentIn rare disease product development, where a placebo control group may not be an option, a single-arm trial can be a successful approach. Gain insight into the regulatory considerations for single-arm trials.
-
![GettyImages-1189687523 AI]( "The Pharmaceutical Industry: 2024 (And Beyond) Predictions")
The Pharmaceutical Industry: 2024 (And Beyond) PredictionsDCTs, RWD, IRA … our industry predictions for 2024 are filled with acronyms. As we delve into 2024, explore what trends are hot ― and not ― for the coming year, and their impact on the industry.
-
![GettyImages-1415642842 data cloud]( "Solving The Puzzle Of Real-World Data/Evidence")
Solving The Puzzle Of Real-World Data/EvidenceGain insight from several industry experts on how real-world data can be used to advance clinical research and enhance the landscape of therapeutic product development.
-
![GettyImages-1201227832 data]( "Real-World Data Vs. Real-World Evidence")
Real-World Data Vs. Real-World EvidenceUnearth the ways real-world data (RWD) and real-world evidence (RWE) in clinical R&D can be used to provide additional validation for new therapies and drugs regarding their efficacy, safety, and value.
-
![GettyImages-184363534-world]( "Real-World Evidence - Where Are We Now?")
Real-World Evidence - Where Are We Now?Notwithstanding ongoing confusion over the concepts of “real-world data” and “real-world evidence” in 2022, more than 5 years after the passage of the 21st Century Cures Act, the FDA continues to evaluate such data and evidence as it considers regulatory decisions.
